HOXD4 and central nervous system cancer: Univariate analysis demonstrated that group with low HOXD4 expression had a considerably better OS than group of high HOXD4 expression in total glioma patients (Figure 3Ep<0.001) and WHO II (Figure 3Fp<0.001), III (Figure 3Gp=0.012).